Moderna, Inc. said that on April 19, Moderna announced preliminary clinical trial results of a booster formulation vaccine. mRNA-1273.211 This is the first combination vaccine that the company has developed. and is currently undergoing clinical efficacy and safety testing in volunteers.
Vaccine mRNA-1273.211 It is a blend of the original breed. and beta species in equal quantities, half each Compared to the current 50 mcg standard mRNA-1273 booster vaccination, the 50 mcg mRNA-1273.211 vaccine was able to induce immunity against omikron strains. and other species of concern, delta and beta, were at higher levels. and higher levels of immunity It was still measured at 6 months later.
in terms of immunity to omikron of the combination booster syringe vaccine The new mRNA-1273.211, measured one month post-injection, was found to have levels that were approximately 2.20 times higher than that of the current standard booster syringe vaccine (1408 vs. 629). Immunity to omikron remained at 2.15 times higher levels (317 vs 146).
Safety of Vaccination Syringe Formulations mRNA-1273-211 at a dose of 50 mcg showed that the subjects were generally well tolerated by the vaccine. The adverse reactions observed were similar to those reported with the standard 50 mcg vaccine, the current booster injection. Most of the symptoms were mild to moderate.
Stefan Balzel, Chief Executive Officer of Moderna, Inc., said the data obtained from the test for the booster-formula vaccine. mRNA-1273.211 which is the first combination vaccine developed The test results showed that Although this combination vaccine does not contain the mRNA of the omikron strain, it does not contain mRNA. But it can stimulate immunity against omikron. and other species of concern at a higher level than the standard formula vaccine
This shows that the strategies planned to deal with the worrisome strains of the virus. and started operating since Feb. Last year was on the right track.
In addition, Moderna is in phase 2/3 clinical trials of another new booster vaccine, mRNA-1273.214 which is a vaccine formulated with a combination of original strains and omikron species It is expected that the preliminary test results Will come out within the 2nd quarter of 65 by both vaccines mRNA-1273.211 and mRNA-1273.214 that was developed as an option for use as a new booster vaccine to be produced at the end of this year
“We are convinced that the two-strain combination booster vaccine It will be a new vaccine that can be used to fight new strains of virus. that may occur in the future The current version of the booster vaccine When using stimulation injection as the 3rd or 4th needle from the data from the actual use in many countries around the world It has been shown that it can still prevent serious infections. And the need to be hospitalized is good,” Mr Stefan said.